Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026
Key Highlights
- ➤Q3 2026 scan volume grew 85% year over year
- ➤Nine-month 2026 scan volume increased 117%
- ➤CLARITY trial expanded to eleven sites with revised enrollment criteria
- ➤$14.2 million cash anticipated to fund 300-patient CLARITY trial into second half of 2027
Expert Statements
Brent Ness, Chief Executive Officer of Aclarion
“The third quarter was a strong one for Aclarion, reflecting the growing interest among physicians in what Nociscan can offer their patients with chronic low back pain.”
Brent Ness, Chief Executive Officer of Aclarion
“Scan volumes grew 85% year-over-year and 117% for the first nine months of 2026, and our clinical program is advancing on multiple fronts.”
Brent Ness, Chief Executive Officer of Aclarion
“The European Spine Journal publication adds to our growing evidence base, and CLARITY is now enrolling at eleven sites under revised criteria designed to accelerate recruitment and strengthen the study's real-world applicability.”
* 85% year-over-year scan volume growth in Q3 2026, contributing to 117% growth for the nine months ended September 30, 2026 * European Spine Journal publishes peer-reviewed data supporting MRS as a potential viable alternative to provocative discography * CLARITY trial expanded to eleven clinical sites with updated enrollment criteria to accelerate recruitment * Overall CLARITY trial duration remains on track, with an update on enrollment progress and anticipated initial readout timing by year-end * $14.2 million in cash, providing anticipated runway into the second half of 2027 and resources to fully fund the 300-patient CLARITY trial BROOMFIELD, Colo., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a Shareholder Letter from Chief Executive Officer Brent Ness providing an update on the Company’s momentum and value-creating priorities for the quarter ended September 30, 2026.
Get started
Create a free account to read the full story.